MA Momoh1 
,
MO Adedokun2,
MU Adikwu1,
CE Ibezim1
For correspondence:- Momoh Email: jointmomoh@yahoo.com Tel:+2348037784357
Received: 2 October 2013 Accepted: 16 March 2014 Published: 25 July 2014
Citation: Momoh M, Adedokun M, Adikwu M, Ibezim C. In vitro Evaluation of PEGylated-Mucin Matrix as Carrier for Oral Delivery of Metformin Hydrochloride. Trop J Pharm Res 2014; 13(7):1039-1045 doi: 10.4314/tjpr.v13i7.5
© 2014 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To formulate metformin hydrochloride-loaded PEGylated-mucin microparticles and evaluate their in vitro properties.
Method: Three different formulations of metformin hydrochloride (MTH) (PEG-M1, PEG-M2 and PEG-M3) were prepared using PEGylation method. PEG-8000 and snail mucin, in a ratio of 1:3, were PEGylated together using solvent interaction principle. Loading of MTH into the matrix was by diffusion method and the microparticles characterized for particle size, zeta potential, polydispersity index, stability and in vitro release in phosphate buffer (pH 7.4).
Results: Maximum yield and encapsulation were 97 and 87 % respectively. Zeta potential was -37.7, - 42.3 and -46.2 mV for PEG-M1, PEG-M2 and PEG-M3 with a corresponding polydispersity index (PDI) of 0.320, 0.374 and 0.398, respectively. Particles size was 85, 115, and 145 µm for PEG-M1, PEG-M2 and PEG-M3, respectively, and they showed a unimodal distribution. Drug release was biphasic and exhibited controlled release pattern with maximum release of 92 % in 18 h compared to 81 % in 6 h for the conventional formulation.
Conclusion: Extended release metformin hydrochloride formulations were successfully developed using PEGylated mucin matrices.
Archives
News Updates
Fulltext in PDF